Sanjay G. Patel, MD

Sanjay G. Patel, MD

University of Oklahoma

Norman, Oklahoma

Sanjay G. Patel, MD, completed his undergraduate training in Biomedical Engineering at Vanderbilt University. He proceeded to complete medical school at Vanderbilt University in Nashville, Tennessee, and urologic surgery training at Vanderbilt University Medical Center. After completing a Society of Urologic Oncology Fellowship at the University of Chicago, he joined the faculty as an Assistant Professor in the Department of Urology at the University of Oklahoma in Oklahoma City. Dr. Patel treats all urologic cancers (adrenal, kidney, ureter, bladder, urethra, and testicular cancer) utilizing open, laparoscopic, and robotic surgery techniques. He has a particular interest in the use of minimally invasive robotic approaches to treat urologic malignancies and has extensive robotic surgery experience. He oversees the Bladder Instillation Clinic, where patients’ bladders are directly treated with immunotherapy and chemotherapy to treat superficial bladder cancer. He is also developing techniques to perform intracorporeal robotic urinary diversions, where he is using minimally invasive robotic techniques to create bladders out of the intestinal tract. Dr. Patel works with the Department of Engineering at the University of Oklahoma to develop novel diagnostic and therapeutic technologies to treat urologic disease. He also has an interest in genetic and molecular profiling of cancers, and how that kind of profiling can be used to guide treatment of urologic cancer.


Articles by Sanjay G. Patel, MD

Blue Light vs. White Light Cystoscopy for NMIBC

Sanjay G. Patel, MD, Assistant Professor of Urology at the University of Oklahoma in Oklahoma City, considers the benefits of blue light versus white light cystoscopy for non-muscle-invasive bladder cancer (NMIBC) imaging. He goes over the importance of good imaging in minimizing progression and recurrence, then looks at the evidence behind blue light cystoscopy, highlighting the improved rates of detection of Ta, T1, and CIS tumors compared to white light cystoscopy. Dr. Patel also notes that these improved rates of detection appear to translate to reduced rates of recurrence and progression as well as increased time to recurrence and progression. He concludes by looking at guideline recommendations on when to use blue light cystoscopy.

Read More

Robotic Cystectomy and ICUD for Muscle Invasive Bladder Cancer

Sanjay G. Patel, MD, Assistant Professor of Urology at the University of Oklahoma College of Medicine, evaluates oncologic evidence comparing open radical cystectomy to robotic cystectomy. This includes addressing morbidity rates detailed in a recent meta-analysis, and questioning whether open diversion could affect these results. Additionally, Dr. Patel analyzes the learning curve associated with performing a robotic cystectomy. Finally, he explains the cost differences between the two techniques, as well as why a more costly operation and/or hospital stay may still be more indirectly cost-effective down the road.

Read More

Take-Home Messages of AUA 2019

Sanjay G. Patel, MD, reviews some of the more salient updates pertaining to prostate cancer discussed at the American Urological Association’s 2019 Annual Meeting. He covers the following topics: reducing persistent opioid use following radical prostatectomy, results from a pivotal trial of an MRI-guided transurethral ultrasound ablation (TULSA) device, BRCA germline testing, findings from the CALGB 90601 trial, and molecular imaging for patients with biochemical recurrence.

Read More

Perioperative Pathways: What We Know Works

Sanjay G. Patel, MD, outlines the rationale behind implementing Enhanced Recovery After Surgery (ERAS) protocols in order to reduce stress, maintain postoperative physiology, and enhance mobilization for patients undergoing cystectomy. He then reviews the data evaluating different ERAS interventions in each perioperative period.

Read More

Urinary Markers in NMIBC: What’s New?

Sanjay G. Patel, MD, defines challenges in the detection and surveillance of bladder cancer when using FDA-approved biomarkers. He then evaluates newer DNA methylation- , DNA mutations- , and mRNA-based biomarkers and their ability to account for the limitations of traditional markers.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -